Mobile website
Archive > Volume 28 Issue 9 > 2021,28(9):863-868. DOI:10.3872/j.issn.1007-385X.2021.09.001 Prev Next
Expert Forum
Screening strategies for individualized tumor-specific TCR
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Genetically engineered T cell immunotherapy has made breakthroughs in the field of tumor therapy, including chimeric antigen receptor engineered-T (CAR-T) cells and T cell receptor modified-T (TCR-T) cells. Although CAR-T cell therapy presents an attractive clinical efficacy on treatment of hematological tumors, CAR-T cells can only recognize tumor cell membrane antigens (accounting for approximately 10% of all cellular antigens); However, TCR-T cells can recognize intracellular antigens presented by human leukocyte antigens (HLAs), so TCR-T cells can recognize more types of tumor antigens, and then realize a reasonable supplement to CAR-T cells. TCR-T cells needs to recognize both intracellular antigens and corresponding HLAs, while the HLA types and tumor antigens in different patients may present huge difference, therefore, it is necessary to customize individualized TCR-T cells for each/each type of cancer patient, in which screening the TCR that specifically recognizes tumor antigens is the key point. Currently, there are two main strategies for screening TCR, targeting "known" tumor antigens and targeting "unknown" tumor antigens, and each has its own applicability. A suitable screening method should be developed for each patient to prepare a variety of tumor-specific TCR-T cells, so as to achieve individualized TCR-T cell therapy for tumor treatment.
Keywords:
Project Supported:
Project supported by the Natural Science Foundation of China (No. 81972880, No. 82003246)
Clc Number:
